Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.

Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.

Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.

Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.